# Safety and Efficacy of Olesoxime (TRO19622) in 3-25 Years SMA Patients.

> **NCT01302600** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 165 (actual)

## Conditions studied

- Spinal Muscular Atrophy Type II
- Spinal Muscular Atrophy Type III Non Ambulant

## Interventions

- **DRUG:** Olesoxime
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01302600
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2013-10
- **Final completion:** 2013-10
- **Target enrollment:** 165 (ACTUAL)
- **Last updated:** 2016-11-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01302600

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01302600, "Safety and Efficacy of Olesoxime (TRO19622) in 3-25 Years SMA Patients.". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT01302600. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*